© 2005 Foundation for Promotion of Cancer Research
Multipoint Oncology Teleconference, Japan |
Multipoint Oncology Teleconference, Japan
This teleconference has been held on a weekly basis (on Thursday evenings) as a good opportunity for the discussion of important issues in clinical oncology. Nowadays, this plenary meeting among the major cancer centers is indispensable for maintaining the high standard of quality of cancer clinics throughout Japan.
Review (April, 2005 series)
April 7: Advanced treatment for hepatocellular carcinoma (moderated by Dr Sasaki, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka). As a treatment for hepatocellular carcinoma (HCC), surgical resection, percutaneous procedures using ethanol injection and radio frequency ablation, and arterial embolization were discussed. Their relative indication for selecting an appropriate method has previously been controversial. Dr Tominaga (Kobe University) showed the effectiveness of percutaneous hepatic infusion therapy, in which a partial response rate of 64% and a 5-year survival rate of 20% were demonstrated in a phase I/II study. Dr Nagano (Osaka University) reported on continuous hepatic arterial infusion with 5-FU and percutaneous injection of Interferon-alpha for advanced HCC with vascular invasion. Dr Yamada (Osaka Medical Center for Cancer and Cardiovascular Diseases) discussed stereotactic radiation therapy with arterial infusion therapy for HCC with massive portal vein embolism, in which a 1-year survival rate of 74% could be achieved. Dr Kubo (Osaka City University) stressed the importance of viral infection to the background of HCC therapy, and the future study of anti-HCC viral therapy.
April 14: Treatment strategy for recurrent or refractory non-Hodgkin's lymphomas (moderated by Dr Kurosawa, Hokkaido Cancer Center, Sapporo). Despite various treatments for recurrent or refractory non-Hodgkin's lymphoma, outcome has not improved and long-term survival has rarely been achieved. Therefore, intensive chemotherapy with auto-PBSCT is being attempted in selected patients. The indication of radiation treatment has also been revised. Dr Aikawa (Hokkaido Cancer Center) reported on the outcome of ESHAP regimen as a second-line chemotherapy for 37 patients with DLBCL and CR rate of 35%. Dr Kiyama (Sapporo Kita-Nire Hospital) highlighted the indication of dose-intensive chemotherapy with auto-PBST as a salvage treatment. Dr Hasegawa (Hokkaido Cancer Center) reported on the outcome of radiation therapy for recurrent lymphoma after complete remission. He stressed that radiation treatment might prolong survival even for lymphomas with systemic spread.
April 21: Treatment for hepatocellular carcinoma (HCC) (moderated by Dr. Takezaki, National Kure Medical Center, Hiroshima). As for the treatment of HCC, surgical resection, INF-therapy, and liver transplantation were extensively discussed. Dr Kohno (Kure Medical Center) stressed the importance of controlling recurrence by INF therapy aiming at sero-negativeness. Dr Kurozumi (Kure Medical Center) reported on the outcome of radio frequency therapy for 52 cases with HCC, in which 3-year survival resulting from radio frequency therapy was comparable to surgery for small-sized HCC with low JIS score. Dr Asahara (Hiroshima University) reviewed the present status of liver transplantation from living donors for HCC with severe liver cirrhosis. Based on 59 cases who underwent this procedure, it was concluded that HCC with Child-Pugh B should be indicated for liver transplantation as the initial treatment, whilst HCC with Child Pugh A should be managed by hepatic resection.
April 28: Indication and evaluation of postoperative treatment for head and neck cancer (moderated by Dr Matsuura, Miyagi Cancer Center, Sendai). Postoperative adjuvant treatment after surgery in head and neck cancer has not been defined. The clinical significance of postoperative radiation therapy after radical neck dissection was discussed by Dr Hasegawa (Aichi Cancer Center) and Dr Fujii (Osaka Medical Center), and was mainly indicated for multiple station metastasis and/or extranodal invasion of metastatic cancer tissue. The outcome suggests an improvement in local control and long-term survival. Dr Matsuura (Miyagi Cancer Center) reported on postoperative radiation therapy and chemotherapy for oro- and naso-pharyngeal cancer with nodal disease. No survival benefit was observed by adding postoperative treatment.
For Japanese readers, detailed information of the conferences, including videos and slides of the presentations, are available at http://www.ncc.go.jp/jp/ncc-cis/pro/vod/index.html
Institutions networked by a multipoint teleconference system: National Hospital Organization Hokkaido Cancer Center, Aomori Prefectural Central Hospital, Iwate Prefectural Central Hospital, Miyagi Cancer Center, Yamagata Prefectural Central Hospital, Ibaraki Prefectural Central Hospital, Niigata Cancer Center, Gunma Prefectural Cancer Center, National Cancer Center, East, National Cancer Center, Chiba Cancer Center, Saitama Cancer Center, Shizuoka Cancer Center, Aichi Cancer Center, Osaka Medical Center for Cancer and Cardiovascular Diseases, National Hospital Organization Kure Medical Center, National Hospital Organization Shikoku Cancer Center, National Hospital Organization Kyusyu Cancer Center.
|
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||